Rosglitazone: what next?

What are the next steps for prescribers reviewing patients on rosiglitazone-containing products? The National Prescribing Centre (NPC) has published a blog post saying that this is an opportunity to review individual patients’ medicines and that as well as considering alternatives, patients and prescribers should review the target blood glucose they are aiming for, given the uncertainty over the benefits of intensive glucose control. Rosiglitazone-containing products will not be available in the UK after 21 October. In August, NICE published a menu of potential indicators for the 2011/2012 Quality and Outcomes Framework, which included a higher target for glycaemic control.